Decoding AML: How Advanced Genetic Testing is Changing Leukemia Care
"A comprehensive look at copy number abnormalities and loss-of-heterozygosity and how they're revolutionizing acute myeloid leukemia diagnosis and treatment."
Acute myeloid leukemia (AML) is a complex group of blood cancers affecting myeloid precursor cells. Diagnosing AML accurately and predicting its course requires a multifaceted approach, combining traditional methods with cutting-edge genetic analysis. Key to this is identifying structural genomic abnormalities which include balanced chromosomal rearrangements as well as copy number variations.
Traditionally, karyotype analysis has been the standard for detecting these abnormalities. However, it has limitations in resolution and success rate. Furthermore, examination for possible copy-neutral loss-of-heterozygosity (CN-LOH) in leukemia cells is at present not routinely performed in the clinical setting. Chromosomal microarray (CMA) analysis is a widely available assay for CNAs and CN-LOH in diagnostic laboratories, but there are currently no guidelines how to best incorporate this technology into clinical testing algorithms for neoplastic diseases including AML.
This article explores how advanced genetic testing, particularly chromosomal microarray analysis (CMA), is transforming AML diagnosis and treatment. We'll break down complex concepts like copy number abnormalities (CNAs) and copy-neutral loss-of-heterozygosity (CN-LOH), and show how they provide critical insights for personalized medicine.
AML Burden and Age-Related Impact
The American Cancer Society estimates that 22,720 people in the United States will be diagnosed with AML in 2026—12,160 males and 10,560 females—and estimates 11,500 AML deaths, including 6,520 males and 4,980 females. Most cases are expected in adults. SEER notes that AML death rates are higher among people 65 and older, while leukemia treatments can often control the disease and its symptoms. A 2025 study abstract describes analysis of U.S. Cancer Statistics data covering incident AML cases from 1999 to 2021, examining incidence patterns by age, sex, and race.
Diagnosis and Its Evolving Challenges
AML diagnosis, risk assessment, monitoring, and treatment have changed substantially over the last decade, according to a 2025 update. The review of adjunctive diagnosis says standard procedures are established, but traditional methods can have limitations in efficiency, accuracy, and standardization; it notes AI applications in medical image analysis and flow cytometry. Medscape’s guideline overview says most AML subtypes are distinguished from related blood disorders by more than 20% blasts in the bone marrow. For patients unable to receive intensive chemotherapy followed by consolidation, with or without a stem cell transplant, a 2025 review describes prognosis as suboptimal.
What are CNAs and CN-LOH, and Why Do They Matter in AML?
In AML, structural genomic abnormalities play a vital role, influencing how the disease develops and responds to treatment. These include:
- Deletions: Loss of genetic material, such as the deletion of 5q or 7q, which often indicates a poorer prognosis.
- Duplications or Amplifications: Extra copies of certain genes, like FLT3, that can drive uncontrolled cell growth.
Genome Mapping and AML Research
A prospective genome-sequencing study comparing the approach with conventional cytogenetics reported an average of 7.5 gene aberrations per case across a list of 109 genes implicated in AML or MDS: an average of 3.9 losses, 3.1 gains or amplifications, and 0.5 structural variants. A study of optical genome mapping (OGM) reports that copy-neutral loss of heterozygosity (CN-LOH) is not routinely assessed in AML despite potential clinical relevance, and that combining OGM labels with SNP co-occurrence strengthens confidence in CN-LOH calls and provides allele-state information in copy-neutral regions. A separate study focuses on copy-number alterations and CN-LOH in elderly patients with NPM1-mutated AML, an area its authors describe as relatively unexplored in elderly-specific cohorts.
AML and ALL: Different Cell Lineages
AML and acute lymphoblastic leukemia (ALL) are cancers of the blood and bone marrow, but they involve different cell lineages. In AML, the marrow produces too many myeloblasts, while in ALL it produces too many lymphocytes. A review of both diseases examines their pathophysiology, classification, and risk stratification, and emphasizes that these factors inform treatment strategies and prognosis. The available source material identifies these differences but does not provide comparative survival figures.
The Future of AML Diagnostics: Personalized Treatment Through Advanced Testing
CMA is not the only tool being used in AML diagnostics. NGS-based approaches for genome-wide evaluation for CNAs and CN-LOH are also becoming feasible in the future.
Real-World AML Care and Unequal Access
A 2023 report on a real-world study of newly diagnosed acute leukemia in Latin American clinical practices describes treatment patterns and outcomes in a setting where published epidemiology and treatment-pattern data had been limited. A related report says AML prognosis generally worsens with age and that curative therapies may be unavailable to older patients and people with significant comorbidities because of high morbidity. Another report notes that Latin American AML has a younger median age at diagnosis—40–47 years—than registries in the United States, United Kingdom, and Sweden, where the reported median is 64–67 years. The American Society of Hematology case study illustrates an individual presentation: a 47-year-old woman sought emergency care with fatigue, shortness of breath, and worsening exercise tolerance over two weeks.
As our understanding of AML genetics deepens, advanced testing methods like CMA will play an increasingly crucial role. By identifying specific CNAs and CN-LOH, doctors can better:
<ul><li>Refine risk stratification</li><li>Predict treatment response</li><li>Personalize therapy</li><li>Ultimately, improve outcomes for people living with AML</li></ul>